Login
$NVAX
$8.07 +$0.01 (0.12%) After hours

$NVAX SEC Filings

Filed On Filing
10 Nov 2026 SCHEDULE 13G
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

GAITHERSBURG, Md., November 5, 2026 – Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended September 30, 2026.

29 Oct 2026 8-K: Regulation FD Disclosure; Other Events

The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease1

16 Oct 2026 SCHEDULE 13G
16 Oct 2026 SCHEDULE 13D/A
07 Aug 2026 SCHEDULE 13G
06 Aug 2026 FORM S-8
06 Aug 2026 8-K: Results of Operations and Financial Condition

Press Release Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights • Reported total revenue of $57 million for the second quarter of 2026 and raised full- year 2026 Revenue Framework • Improved GAAP Combined R...

06 Aug 2026 10-Q
23 Jun 2026 Form 4: Rodgers Richard J, Director

Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units · Received 18,880 shares by exercise or conversion

23 Jun 2026 Form 4: King Rachel K., Director

Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units · Received 18,880 shares by exercise or conversion

23 Jun 2026 Form 4: Douglas Richard, Director

Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units · Received 18,880 shares by exercise or conversion

23 Jun 2026 Form 4: Mcglynn Margaret G, Director

Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units · Received 18,880 shares by exercise or conversion

23 Jun 2026 Form 4: Mott David M, Director

Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units · Received 18,880 shares by exercise or conversion

23 Jun 2026 Form 4: Alton Gregg H, Director

Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units · Received 18,880 shares by exercise or conversion

23 Jun 2026 Form 4: Shiver John W., Director

Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units

23 Jun 2026 Form 4: Newton Charles W., Director

Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units

23 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 18, 2026, Novavax, Inc. (the “Company”) held its Annual Meeting, at which stockholders as of April 23, 2026 (the “Record Date”) were entitled to vote. As of the Record Date, there were 164,427,429 shares of the Company’s common s...

27 May 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support